- Home
- / Akcea Therapeutics
Akcea Therapeutics
Akcea Therapeutics Summary
Company Summary
- Overview
- Akcea Therapeutics is a late-stage biopharmaceutical company developing drugs for the treatment of cardiometabolic diseases caused by lipid disorders. It focuses on four drugs: Volanesorsen, AKCEA-APO(a)-LRx, AKCEA-ANGPTL3-LRx, and AKCEA-APOCIII-LRx, that are based on antisense technology.
- Type
- Subsidiary
- Status
- Active
- Founded
- 2014
- HQ
- Boston, MA, US | view all locations
- Website
- http://akceatx.com/
- Cybersecurity rating
- ESG rating
Table of Contents
Key People
Duncan Brown, Director, Health Economics & Outcomes Research
Cory Varney, Director, Channel Operations, GP, and Payer Analytics
Louis St. L. O'Dea, Strategic Advisor
Operating MetricsView all
Approval Phase Products
1
Jun, 2017
Phase III Trials Products
1
Jun, 2017
Phase II Trials Products
1
Jun, 2017
LocationsView all
2 locations detected
Boston, MA HQ
United States
22 Boston Wharf Rd 7th Floor
Cambridge, MA
United States
55 Cambridge Pkwy #100
Akcea Therapeutics Financials
Summary Financials
- Cash (FY, 2016)
- $7.9M
- EBIT (FY, 2016)
- ($83.5M)